Skip to main content

Table 2 Treatment completion and reasons for non-completion by treatment regimen, Norway 2016

From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Treatment completion

3RHI

daily

3RPHII

weekly

OtherIII

Total

Number of individuals

399

306

21

726

Duration of treatment (days), median [IQR]*

90 [73–156]

77 [70–98]

–

–

Treatment completion

 Completed according to physiciana

357 (89.5)

284 (92.8)

17 (80.9)

658 (90.6)

 Missing information

3 (0.8)

4 (1.3)

–

7 (1.0)

 Incomplete treatment

39 (10)

18 (5.9)

4 (19.0)

61 (8.4)

Reasons for incomplete treatment

 LTBI excluded

4 (1.0)

–

–

4 (0.6)

 Diagnosed with TB disease

1 (0.3)

–

 

1 (0.1)

 Patient choice

4 (1.0)

2 (0.7)

–

6 (0.8)

 Lost to follow-up

1 (0.3)

3 (1.0)

–

4 (0.6)

 Other or unknown

3 (0.8)

2 (0.7)

 

5 (0.7)

 Termination due to adverse effectsb

26 (6.5)

11 (3.4)

4 (19.0)

41 (5.6)

  Hepatotoxicity (grade 1–2)c

8 (2.0)

–

–

8 (1.1)

  Hepatotoxicity (grade 3–4)c

5 (1.6)

2 (0.7)

1 (4.8)

8 (1.1)

  Gastrointestinal symptoms

10 (2.5)

8 (2.6)

2 (9.5)

20 (2.8)

  Fatigue

6 (1.5)

8 (2.6)

1 (4.8)

15 (2.1)

  Flu-like symptoms

2 (0.5)

4 (1.3)

1 (4.8)

7 (1.0)

  Skin rash

2 (0.5)

1 (0.3)

1 (4.8)

4 (0.6)

  Peripheral neuropathy

1 (0.3)

  

1 (0.1)

  Joint pain

–

2 (0.6)

–

2 (0.3)

  Other symptomsd

2 (0.5)

3 (1.0)

2 (9.5)

7 (1.0)

  1. Data are presented as n (%) or median [interquartile range]
  2. I3RH: rifampicin (R) and isoniazid (H) daily for three months
  3. II3RPH: rifapentine (RP) and isoniazid (H) in 12 weekly doses
  4. IIIOther: rifampicin (R) monotherapy daily for four months (n = 5), Isoniazid (H) monotherapy for six months (n = 13) or combination therapy for TB disease (n = 2) and missing information about drug regimen (n = 1)
  5. *Duration of treatment for those where the clinician reported the treatment as completed
  6. aThe responsible clinician reported that the planned treatment was completed
  7. bMany reported more than one adverse effect
  8. cSeverity of hepatotoxicity was classified according to Common Terminology Criteria for Adverse Events (CTCAE), ULN = upper limits of normal value for serum levels of liver function, grade 1 (>ULN -3.0 × ULN), grade 2 (> 3.0–5.0 × ULN), grade 3 (> 5.0–20.0 × ULN), and grade 4 (> 20.0 × ULN)
  9. dIncludes headache, sleep disorder, and unstable international normalized ratio (INR) for prothrombin time